OverviewSuggest Edit
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear. The Company has developed a proprietary technology that is designed to deliver a drug that is retained in the ear for an extended period of time following a single local administration. Utilizing this technology, Otonomy has advanced multiple product candidates into development and launched its first product, OTIPRIO®.
OTIPRIO is a single-dose, physician-administered antibacterial and the first product approved by the FDA for the treatment of pediatric patients with bilateral otitis media with effusion undergoing ear tube placement.
| Type | Public | |
| Founded | 2008 | |
| HQ | San Diego, US | Map |
| Website | otonomy.com |
Recent NewsAll News
- Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update
- Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program
- ALK Enters into Co-Promotion Agreement with Otonomy for OTIPRIO® (ciprofloxacin otic suspension), the First and Only Single-Dose Treatment for Acute Otitis Externa (Swimmer's Ear)
- Otonomy to Present at Raymond James 2020 Human Health Innovation Conference
Key People/Management at Otonomy
David A. Weber
Chief Executive Officer, President and Board Member
Carla da Luz Boren
General Counsel and Head of Human Resources
Julie D. Burgess
Vice President, Finance and Administration
Paul E. Cayer
Chief Financial & Business Officer
David Skarinsky
Vice President, Clinical
Barbara M. Finn
Vice President, Regulatory Affairs and Quality Assurance
Otonomy Office Locations
Otonomy has an office in San Diego
San Diego, US (HQ)
4796 Executive Dr
Otonomy Financials and Metrics
Otonomy Revenue
Otonomy's revenue was reported to be $600 k in FY, 2019
| USD | |
|---|---|
Revenue (Q2, 2020) | 10.0k |
Gross profit (Q2, 2020) | (501.0k) |
Gross profit margin (Q2, 2020), % | (5010%) |
Net income (Q2, 2020) | (11.5m) |
EBIT (Q2, 2020) | (11.1m) |
Market capitalization (14-Sept-2020) | 189.5m |
Closing stock price (14-Sept-2020) | 3.9 |
Cash (30-Jun-2020) | 32.0m |
EV | 175.8m |
Otonomy's current market capitalization is $189.5 m.
- Source: SEC Filings
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 358.0k | 326.0k | 282.0k | 301.0k | 123.0k | 113.0k | 192.0k | 190.0k | 125.0k | 160.0k | 10.0k |
Cost of goods sold | 463.0k | 397.0k | 290.0k | 272.0k | 241.0k | 162.0k | 213.0k | 203.0k | 220.0k | 214.0k | 511.0k |
Gross profit | (105.0k) | (71.0k) | (8.0k) | 29.0k | (118.0k) | (49.0k) | (21.0k) | (13.0k) | (95.0k) | (54.0k) | (501.0k) |
Gross profit Margin, % | (29%) | (22%) | (3%) | 10% | (96%) | (43%) | (11%) | (7%) | (76%) | (34%) | (5010%) |
- Source: SEC Filings
Annual
- Source: SEC Filings
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (27.1m) | (71.3m) | (11.4m) | (25.0m) | (37.5m) | (12.0m) | (23.7m) | (33.7m) | (11.8m) | (23.2m) | |
Depreciation and Amortization | 923.0k | 295.0k | 594.0k | 892.0k | 276.0k | 565.0k | 854.0k | 286.0k | 569.0k | ||
Inventories | 1.2m | 1.2m | 197.0k | 6.0k | |||||||
Accounts Payable | 212.0k | 1.3m | 138.0k | 1.5m | (184.0k) | 321.0k | 123.0k | 837.0k | (90.0k) | (264.0k) | (491.0k) |
- Source: SEC Filings
| USD | FY, 2016 |
|---|---|
Revenue/Employee | 4.9k |
Financial Leverage | 1.1 x |
Otonomy Operating Metrics
| FY, 2016 | |
|---|---|
Patents Issued | 88 |
Patents Pending | 115 |
Phase III Trials Products | 2 |
Products | 1 |
Otonomy Cybersecurity Score
Otonomy Online and Social Media Presence
226 Twitter followers
Otonomy has 226 Twitter Followers. The number of followers has decreased 1.7% quarter over quarter
Otonomy's Trends
Otonomy News and Updates
August 04, 2020
Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Conference call and webcast today at 5 p.m. ET
August 03, 2020
Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program
Compound has potential to benefit patients with severe hearing loss Compound has potential to benefit patients with severe hearing loss
June 17, 2020
ALK Enters into Co-Promotion Agreement with Otonomy for OTIPRIO® (ciprofloxacin otic suspension), the First and Only Single-Dose Treatment for Acute Otitis Externa (Swimmer's Ear)
ROUND ROCK, Texas, June 17, 2020 /PRNewswire/ -- ALK (ALKB:DC / OMX:ALK B / AKABY / AKBLF) a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies, announced today the signing of an exclusive agreement with Otonomy, a...
June 11, 2020
Otonomy to Present at Raymond James 2020 Human Health Innovation Conference
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, is scheduled to present a company overv…
June 10, 2020
Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020
SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that due to the health, safety and travel concerns of stockholders and federal, state and local government…
June 08, 2020
Otonomy to Host Pipeline Program Update Conference Call and Webcast
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will host a conference call and webcast to review the status and timeline to results for the company’s …
Otonomy Blogs
July 06, 2020
Otonomy Provides Update on OTIVIDEX® Program
Otonomy Provides Update on OTIVIDEX® Program
Content Import
Mon, 07/06/2020 - 16:02
Otonomy Provides Update on OTIVIDEX® Program
July 6, 2020 at 4:02 PM EDT
This release is a backfill from a News Wire
General
Management will review th…
May 12, 2020
Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program
Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program
Content Import
Tue, 05/12/2020 - 08:02
Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss…
May 07, 2020
Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update
Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update
Content Import
Thu, 05/07/2020 - 07:32
Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 7, 2020 at 7:30 AM EDT
This release is a backfill…
February 27, 2020
Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Content Import
Thu, 02/27/2020 - 16:16
Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
February 27, 2020 at 4:15 PM EST
…
February 20, 2020
Otonomy to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
SAN DIEGO , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Otonomy , Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2019 as well as provide a corporate
January 23, 2020
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
Preclinical results to be presented for GJB2 gene therapy hearing loss collaboration and OTO-510 program for cisplatin otoprotection SAN DIEGO , Jan. 23, 2020 (GLOBE NEWSWIRE) -- Otonomy , Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for
Otonomy Frequently Asked Questions
When was Otonomy founded?
Otonomy was founded in 2008.
Who are Otonomy key executives?
Otonomy's key executives are David A. Weber, Carla da Luz Boren and Julie D. Burgess.
How many employees does Otonomy have?
Otonomy has 49 employees.
What is Otonomy revenue?
Latest Otonomy annual revenue is $600 k.
What is Otonomy revenue per employee?
Latest Otonomy revenue per employee is $12.2 k.
Who are Otonomy competitors?
Competitors of Otonomy include Seed, BeyondSpring and Inovio Pharmaceuticals.
Where is Otonomy headquarters?
Otonomy headquarters is located at 4796 Executive Dr, San Diego.
Where are Otonomy offices?
Otonomy has an office in San Diego.
How many offices does Otonomy have?
Otonomy has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies